Adia Nutrition Inc (PK) (ADIA) Quote

Such a phenomenal CEO we have here! It will be difficult not to succeed with him running the show. Plus, a rapidly growing sales team must be smelling big money!

yes some big catalysts upcoming to break us over 10

$ADIA as per usual the CEO does a great job of keeping us in the loop! $ADIA

A quick update! pic.twitter.com/GD61LmlGFa— Adia Nutrition (@ADIA_Nutrition) March 21, 2025

About to go Ballistic ADIA Going OTCQB!

Locked in and Loaded Up! ADIAs Time Has Come! True Valuation Correction UP! About to heat up. Let's Goooo!

audit almost done! OTCQB coming soon $ADIA

A quick update! pic.twitter.com/GD61LmlGFa— Adia Nutrition (@ADIA_Nutrition) March 21, 2025

agreed

Extremely Bullish! ADIA!!!

Uplisting to OTCQB, removal of 25 million shares, opening clinics nationwide, sales of branded stem cells with FDA approval! All coming together! I'm all in!!!$$$$

Also, when more clinics open, and sales of signed stem cell contracts. It's coming, buckle up!

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
March 20, 2025 9:30 AM EDT | Source: Adia Nutrition Inc.
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standards to the new head of the Department of Health and Human Services, and the FDA, advocating for federal alignment to address widespread inconsistencies in stem cell therapies.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243473_fda.jpg

Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243473_fda.jpg

Patients nationwide have long grappled with a troubling issue: many clinics provide low-quality or non-viable—"dead"—stem cells, with no way for recipients to verify potency or quantity. This lack of oversight has eroded trust and limited the promise of regenerative medicine. Adia Med is stepping up to ensure every patient receives live, viable stem cells in the amounts promised, backed by unmatched quality controls.

"Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."

A Robust Standardization Framework
Adia Med's initiative rests on key pillars to fix current shortcomings:
Homologous Use Standards: Guidelines will ensure stem cells are used in line with their natural functions, boosting safety and effectiveness while curbing misuse risks.
Quality Control Protocols: Strict processes for harvesting, processing, and storing stem cells will maintain their therapeutic power, with standards covering donor screening, isolation, and banking.
Third-Party Verification: Every lab nationwide offering stem cell products would be required to provide third-party verification to guarantee a minimum stem cell count and viability for each batch, ensuring a consistent standard of quality, transparency, and reliability across the industry. This auditing ensures transparency and accountability.
Best Practices Development: Collaboration with stem cell experts, ethicists, and practitioners will produce adoptable standards to eliminate variability and enhance patient outcomes.

"Doctors should be getting their stem cells from a lab who has a third-party verified, FDA-validated process which guarantees quality, and we're pushing to make that the industry baseline with umbilical cord stem cells."

"Patients should never have to doubt the viability of their stem cells," said Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're creating a standard where every patient receiving umbilical cord stem cells will receive a certificate from a third party, unequivocally verifying the quantity and viability of their specific batch." This hands-on assurance ensures doctors deliver stem cells from labs with independently verified, FDA-validated processes, setting a new benchmark for quality and boosting patient outcomes across the industry.

Tackling a Pressing Problem
Reports of patients receiving substandard or dead stem cells are rising, often unbeknownst to them. Adia Med's standards, backed by independent verification, will mandate live, viable cells in guaranteed minimum quantities, promising:
Patient Safety: Reduced risks from poor-quality cells or improper use.
Treatment Consistency: Reliable results nationwide, regardless of provider.
Industry Credibility: Ethical standards to eliminate bad actors and restore trust.

Federal Collaboration and Beyond
Adia Med aims to partner with the new head of the Department of Health and Human Services and the FDA, presenting these standards to shape a national framework. "With their leadership, we can end the uncertainty and deliver real benefits," Powalisz added. The company also invites input from regulators, medical professionals, and patient advocates, with participation details forthcoming at www.adiamed.com. Adia invites interested parties to reach out by filling out the contact form at www.adiamed.com.

For inquiries, questions, or further information, you can contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

$ADIA

yep 2 things will move this and break us over 2, otcqb uplist and the 25M OS reduction

Still very bullish here. Q2 should be our breakout quarter, mere weeks away. Just waiting patiently.

Nice update. Stem cell therapy has the potential to revolutionize medicine—but only if it’s safe, standardized, and reliable. Adia Med’s new protocols will set homologous use standards, quality controls, and third-party verification to ensure every patient gets the best treatment possible.

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

news https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-?id=471097

If you dont have any time for the pumpers, why didnt you put them on ignore. Its literally everyone on this board.

I think the real investors are holding back until they see an independent (not a friend) CPA audit, minimum listing on the OTCQB exchange, revenue coming in verified by the independent CPA firm, no more pumping the stock, etc.

I put Natural Trader and Samson8 on ignore. I don't have any use for these type of unprofessional posters as well as pumpers. I invite real professionals for their comments.

clown stock pumping

going over .10 lol buy it then

Promoters leave this one and move over to INKW?

Quick someone slap 100 shares to make it look like people are buying this.........

Adia Med to Expand Treatment Offerings with Therapeutic Plasma Exchange (TPE) Across All Future Full Clinic Locations
Winter Park, Florida--(Newsfile Corp. - March 17, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative healthcare solutions, is thrilled to announce that its subsidiary, Adia Med, will ensure that all future full clinic locations across the United States will offer Therapeutic Plasma Exchange (TPE), with its current location already offering this advanced treatment as of today. These full clinics, which will also perform Hematopoietic Stem Cell Transplantation (HSCT) for various conditions using state-of-the-art apheresis machines, will integrate TPE into their offerings, leveraging the same cutting-edge equipment. This forward-thinking expansion will unlock a wide range of applications, including potential benefits for Alzheimer's disease, reinforcing Adia Med's commitment to pioneering patient care.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243472_1.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243472_70824-9959585.jpeg

TPE, a procedure that utilizes an apheresis machine to remove and replace a patient's plasma, will target harmful substances—such as autoantibodies, immune complexes, and toxins—in the bloodstream, offering hope for numerous conditions, including neurodegenerative diseases like Alzheimer's. With all future Adia Med full clinics set to utilize apheresis technology for HSCT, they will seamlessly adopt TPE, maximizing the potential of this sophisticated equipment. The current Adia Med location, now offering TPE, marks the first step in this transformative vision.

"We are excited to announce that all our future full clinics will provide TPE, a treatment with immense potential to change lives, including for those affected by Alzheimer's," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care. As one of just three clinic networks in the U.S. with this technology, we will continue to lead the charge in advanced medical solutions."

Studies have highlighted the promising benefits and versatility of TPE across various conditions, including Alzheimer's disease. A study published in Alzheimer's & Dementia explored the AMBAR trial, which showed that TPE combined with albumin replacement slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer's, suggesting that removing amyloid-beta proteins and other toxic plasma components could play a key role in disease management. Notably, insurance has already covered TPE for Alzheimer's applications in some cases, reflecting growing recognition of its potential.

Additionally, research in Transfusion and Apheresis Science demonstrated TPE's ability to reduce mortality in moderate-to-critical COVID-19 patients, with a risk ratio of 0.41 (95% CI 0.24 to 0.69), underscoring its broader life-saving potential. The American Society for Apheresis (ASFA) also recognizes TPE as a first-line therapy for conditions like Guillain-Barré Syndrome, Myasthenia Gravis, and Thrombotic Thrombocytopenic Purpura (TTP), where it will swiftly remove disease-causing agents to improve outcomes. Future applications may extend to autoimmune disorders, other neurological conditions, and certain drug overdoses, showcasing TPE's extensive therapeutic reach.

The national average cost for TPE ranges from $4,000 to $6,000 per patient, depending on factors like facility fees, the number of sessions required, and regional pricing differences. With Florida's large retiree population—over 4.5 million residents aged 65 and older, many of whom face age-related conditions like Alzheimer's and autoimmune disorders—Adia Med sees a significant market for this treatment. This demographic, combined with the state's growing healthcare infrastructure, positions Florida as an ideal hub for expanding TPE access, addressing a critical need among retirees seeking advanced therapeutic options.

Patients and healthcare providers eager to explore TPE and other services at Adia Med's clinics can visit www.adiamed.com or contact 321-788-0850 for more information as these offerings roll out.

https://www.newsfilecorp.com/release/243472/Adia-Med-to-Expand-Treatment-Offerings-with-Therapeutic-Plasma-Exchange-TPE-Across-All-Future-Full-Clinic-Locations

$ADIA

Snake oil

very nice news , going over .10 today https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-to-Expand-Treatment-Offerings-with-Therapeutic-Plasma-Exchange-TPE-Across-All-Future-Full-Clinic-Locations?id=470666

yea I think itll do it today doesnt take much to do it

General question here but why is Rebecca Miller the CFO of ADIA buying the Reg A of Steve Carnes other companies (INKW and GMZP) and then flipping the shares? Seems like a self enrichment scheme like they got convicted of by the SEC before.

Pump and dump

"We're committed to innovation, accessibility, and sustainable growth for our stakeholders."

The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.

The OTCQB uplisting process, now in clear sight with the shell risk designation lifted

"This is just the start."

These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue

This Comany is Something Special!!! Watch!!!

This Comany is Something Special!!! Watch!!!

Adia will alway do what is in the best interest of the company and Adia's shareholders.

https://www.newsfilecorp.com/release/242492/ADIA-Nutrition-Inc.-Ignites-2025-with-February-Breakthroughs-Riding-Adia-Meds-Profitable-January-Triumph

New HIGH OF .095!

Pump and dump

Possibility!

Waiting for $1.00+

Hit .095 Today!

Nice volume came in this afternoon.

Would like to see this back over .10 next week!

$ADIA

dome decent buys coming in at 09 this afternoon

Accumulation

Some interesting buying coming now. All buys today, so far:

A whopping $117 of prop volume to keep the price at .09. I bet none of you pumpers even know the annual report came out this week. That or you dont want to mention it because it states theyll need money and will need to use the Reg A at .005

$ADIA churning green here. just a matter of time before this breaks out.

Plus the company is working with a PCAOB-registered accounting firm to complete a third-party audit—the first step in its plan to uplist to OTCQB and eventually Nasdaq Small Cap!

Here’s why this matters:

✅ OTCQB uplisting = More credibility & transparency 📊
✅ Increased liquidity = More trading volume, stronger price action 💰
✅ Bigger investor base = Institutional money on the horizon 💵
✅ Roadmap to Nasdaq Small Cap is in place 🚀

Way overbought and pumped. Looks like someone bought 100 shares at the close to paint the mark.